Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by The Goldman Sachs Group

Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by equities researchers at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a research report issued on Tuesday,Finviz reports. They presently have a $25.00 target price on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective points to a potential upside of 23.33% from the stock’s current price.

Several other equities analysts have also recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Barclays decreased their price objective on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Bank of America cut their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. Finally, HC Wainwright decreased their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Fifteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $60.47.

Ultragenyx Pharmaceutical Trading Up 2.0%

Shares of RARE stock opened at $20.27 on Tuesday. The firm has a fifty day simple moving average of $22.70 and a two-hundred day simple moving average of $28.39. Ultragenyx Pharmaceutical has a 12 month low of $18.41 and a 12 month high of $42.37. The firm has a market capitalization of $1.96 billion, a PE ratio of -3.47 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period last year, the business posted ($1.39) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the transaction, the chief executive officer owned 658,994 shares of the company’s stock, valued at $15,025,063.20. This trade represents a 7.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Crombez sold 7,029 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $160,261.20. Following the completion of the transaction, the executive vice president owned 76,301 shares in the company, valued at $1,739,662.80. The trade was a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 104,958 shares of company stock worth $2,394,858. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 29,984 shares during the period. Creative Planning bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $454,000. Entropy Technologies LP raised its stake in shares of Ultragenyx Pharmaceutical by 50.2% during the 2nd quarter. Entropy Technologies LP now owns 11,336 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 3,787 shares during the period. DNB Asset Management AS boosted its holdings in shares of Ultragenyx Pharmaceutical by 3.2% in the 2nd quarter. DNB Asset Management AS now owns 14,720 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 452 shares during the last quarter. Finally, Legal & General Group Plc grew its position in Ultragenyx Pharmaceutical by 21.2% during the second quarter. Legal & General Group Plc now owns 313,804 shares of the biopharmaceutical company’s stock valued at $11,410,000 after buying an additional 54,837 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.